Network Pharmacology Deciphering Mechanisms of Volatiles of Wendan Granule for the Treatment of Alzheimer’s Disease

Figure 5

Pathway-disease network analyses results. Red nodes represented diseases while the green nodes represented pathways. The edges represented the interaction between them (abbreviations: AADC: aromatic L-amino acid decarboxylase deficiency; ADHD: attention deficit hyperactivity disorder; ADNFLE: autosomal dominant nocturnal frontal lobe epilepsy; APDS: activated PI3K-delta syndrome; ATS: Andersen-Tawil syndrome; BRS: Brugada syndrome; CAA: cerebral amyloid angiopathy; CFEOM: congenital fibrosis of the extraocular muscles; CMD/MDC: congenital muscular dystrophies; CSGD: congenital systemic glutamine deficiency; CSNB: congenital stationary night blindness; FCD: fleck corneal dystrophy; FPL: familial partial lipodystrophy; FTC: familial tumoral calcinosis; GFND: Glomerulopathy with fibronectin deposits; HD: Hirschsprung disease; HLHS: hypoplastic left heart syndrome; HypoPP: hypokalemic periodic paralysis; IFSHD: isolated follicle-stimulating hormone deficiency; IGEs: idiopathic generalized epilepsies; LADD: lacrimo-auriculo-dento-digital syndrome; LCCS: lethal congenital contracture syndrome; LCD: lattice corneal dystrophies; LDS: Loeys-Dietz syndrome; LGMD: limb-girdle muscular dystrophy; MmD: multiminicore disease; NBIA: neurodegeneration with brain iron accumulation; NDNC: nonsyndromic congenital nail disorder; NSIAD: nephrogenic syndrome of inappropriate antidiuresis; OCD: obsessive compulsive disorder; OHSS: ovarian hyperstimulation syndrome; PEO: progressive external ophthalmoplegia; POH: progressive osseous heteroplasia; TAAD: familial thoracic aortic aneurysm and dissection; and WS: Waardenburg syndrome).